FDA approves Ariad's Iclusig for rare leukemias

12/16/2012 | Fox Business · HealthDay News

Ariad Pharmaceuticals obtained accelerated FDA approval for Iclusig, or ponatinib, to treat patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug, which was cleared three months ahead of schedule, inhibits certain proteins that promote cancer cell development. Iclusig will be sold with a boxed warning on its label about the risk of blood clots and liver poisoning.

View Full Article in:

Fox Business · HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID